Lundbeck's alcohol dependency drug wins EU green light
Key points
- Danish drugmaker Lundbeck won a European green light on Friday for its new alcohol dependency drug Selincro, boosting its product portfolio at a time when its biggest product faces a big drop in sales.
- Lundbeck needs new drugs to replace lost sales from antidepressant Cipralex, sold as Lexapro in the United States and Japan, which is now coming off patent.
- The European Medicines Agency (EMA) said on Friday it recommended approval of Selincro in conjunction with psychosocial support for the reduction of alcohol consumption in adults with alcohol dependence.
- Recommendations from the EMA are normally endorsed by the European Commission within two or three months, implying the drug could be launched in Europe early next year.
Danish drugmaker Lundbeck won a European green light on Friday for its new alcohol dependency drug Selincro, boosting its product portfolio at a time when its biggest product faces a big drop in sales.
Lundbeck needs new drugs to replace lost sales from antidepressant Cipralex, sold as Lexapro in the United States and Japan, which is now coming off patent.
The European Medicines Agency (EMA) said on Friday it recommended approval of Selincro in conjunction with psychosocial support for the reduction of alcohol consumption in adults with alcohol dependence.
Recommendations from the EMA are normally endorsed by the European Commission within two or three months, implying the drug could be launched in Europe early next year.
Selincro, which blocks the action of opioid receptors in the brain, was licensed to Lundbeck from Finland's Biotie Therapies.
Shares in Biotie jumped more than 11 percent on the news, while Lundbeck rose around 1 percent.
Selincro breaks new ground as a treatment for reducing alcohol consumption and Lundbeck CEO Ulf Wiinberg told Reuters last week it was "a bit of a joker in our portfolio" because of uncertainty as to how it will be used.
Analysts currently pencil in only modest sales for the product.
(Reporting by Ben Hirschler; editing by Chris Wickham)
###
Reuters
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Mental Health →
NewsAlcohol-deterrent drugs help long-term abstinence
Studies investigating the long-term outcomes of alcoholism treatment are rare and inconsistent. A nine-year study in the January issue of Alcoholism: Clinical & Experimental Research investigates the occurrence of…
10 January 2006
NewsEli Lilly wins US approval for new depression drug
Eli Lilly & Co. on Wednesday said U.S. regulators have approved its new antidepressant, Cymbalta, a drug that analysts say will be central to the company's growth. Lilly's shares rose 2 percent to $64.50 in electronic…
5 August 2004
NewsAlcohol exposure during pregnancy affects multiple generations
When a mother drinks alcohol during pregnancy, even a small dose, she can increase the chances that the next three generations may develop alcoholism, according to a new study from Binghamton University. A research team…
